Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Guillain-Barré syndrome
Guillain-Barré syndrome
Guillain-Barré syndrome
Synonyms: GBS, Guillain-Barré-Strohl syndrome
Synonyms: GBS, Guillain-Barré-Strohl syndrome
Synonyms: GBS, Guillain-Barré-Strohl syndrome
Drug discovery
11
drugs
With orphan designations
Rare neurological diseases
Guillain-Barré syndrome
Overview
Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy and the most common cause of acute flaccid paralysis worldwide [2][5]. Characterized by ascending paralysis, sensory abnormalities, and autonomic dysfunction, it typically follows infections or vaccinations [5][16]. Diagnosis relies on clinical presentation, cerebrospinal fluid analysis, and nerve conduction studies [6][11]. First-line treatments include IV immunoglobulin (IVIG) and plasma exchange [3][8], with most patients achieving functional recovery despite potential long-term disability [1][16].
Categories: rare neurological diseases
Research Papers
1,600 drug discovery papers about Guillain-Barré syndrome, with 3 first-in-class and 34 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,600 drug discovery papers about Guillain-Barré syndrome, with 3 first-in-class and 34 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-09-11 | P2X7 Receptor in Rare Diseases: Shared Molecular Mechanisms and Therapeutic Implications.
Rare diseases (RDs) are individually uncommon but collectively affect a large global population, and the vast majority still lack effective disease-modifying therapies. With advances in genomics and data-sharing platforms, research has increasingly shifted from a single-disease perspective to the search for convergent molecular pathways that might be shared across clinically distinct entities. In this context, the purinergic P2X7 receptor (P2X7R) has emerged as a putative "shared molecular platform" due to its central role in inflammation amplification, cell death and immune regulation. P2X7R is an ATP-gated ion channel with unique structural and functional features: under high extracellular ATP, it not only forms a non-selective cation channel but can also dilate into a "large pore" permeable to macromolecules, thereby triggering Ca2+overload, NLRP3 inflammasome assembly, reactive oxygen species (ROS) production and apoptotic/necrotic-like cell death. This review briefly outlines the epidemiology of RDs and the structural-functional characteristics of P2X7R, then systematically summarizes current evidence linking P2X7R to multiple rare diseases, including Charcot-Marie-Tooth disease, Guillain-Barré syndrome, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and selected inflammatory and metabolic RDs (CAPS, familial Mediterranean fever, Systemic sclerosis, Dravet syndrome and Gaucher disease). By comparing P2X7R expression and functional alterations, downstream signaling pathways and pharmacological data from animal models across these conditions, we propose that a P2X7R-dependent network centered on a "Ca2+-NLRP3-inflammation/cell death axis" may constitute a common pathogenic backbone for diverse RDs. At the same time, disease-specific spatiotemporal expression patterns of P2X7R in central vs peripheral nervous systems and in immune vs target organ cells confer marked context dependence and "double-edged sword" properties. Finally, we discuss opportunities and challenges for P2X7R-targeted strategies, including the impact of disease stage and sex differences on therapeutic efficacy, and key bottlenecks in translating preclinical findings into clinical benefit. A deeper understanding of both shared and disease-specific roles of P2X7R may provide a conceptual framework and therapeutic entry point for precision stratification and multi-target interventions in rare diseases.
2026-09-08 | A Rare Atypical Cardiac-Arrest Onset of Fulminant Systemic Lupus Erythematosus with Multiorgan Failure, Myocarditis, and AMAN- Variant Guillain-Barré Syndrome Successfully Treated with Multimodal Immunotherapy.
This report highlights a rare, catastrophic presentation of Systemic Lupus Erythematosus (SLE) manifesting as sudden cardiovascular collapse in a patient with no prior autoimmune history. The case is particularly novel due to the concurrent development of the Acute Motor Axonal Neuropathy (AMAN) variant of Guillain-Barré Syndrome (GBS) alongside multiorgan failure, mimicking septic and cardiogenic shock. A 49-year-old woman suffered an out-of-hospital cardiac arrest following acute gastroenteritis, characterized by recurrent ventricular fibrillation and tachycardia. She rapidly developed multiorgan failure, including severe myocardial dysfunction (EF 29%), acute kidney injury, metabolic acidosis, and altered consciousness. While the initial presentation suggested sepsis, subsequent testing revealed positive antinuclear antibodies, lupus anticoagulant, and hypocomplementemia, meeting ACR/EULAR criteria for SLE. Electrophysiological studies for persistent weakness confirmed AMAN-type GBS. Following an aggressive multimodal immunotherapy regimen of corticosteroid pulses, Intravenous Immunoglobulin (IVIG), and rituximab, the patient achieved significant recovery of cardiac, renal, and neurological functions. This case demonstrates that SLE can present as a life-threatening "autoimmune storm" mimicking sepsis or primary heart failure. Early identification is vital in atypical critical illness, as aggressive immunotherapy can reverse even severe multiorgan dysfunction. Clinicians should consider autoimmune screening in cases of unexplained cardiac arrest and multiorgan failure to prevent diagnostic delays and improve outcomes.
2026-09-07 | [Oral urea in the management of inappropriate antidiuretic hormone secretion syndrome associated with Guillain-Barré syndrome, severe dysautonomia, and pheochromocytoma ‒ An exceptional clinical case].
Introduction and case report: we report the case of an 82-year-old man with pheochromocytoma and colon adenocarcinoma who developed rapidly progressive Guillain-Barré syndrome with severe dysautonomia following a recent SARS-CoV-2 infection. In this setting, he developed progressive hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH). Marked autonomic instability related to the coexistence of Guillain-Barré syndrome and pheochromocytoma limited conventional therapeutic options. After an inadequate response to fluid restriction and oral sodium chloride supplementation, oral urea therapy was initiated, resulting in a gradual and safe correction of serum sodium without significant adverse events. Normalization of serum sodium enabled completion of preoperative management and successful adrenalectomy and colon cancer surgery, without recurrence of hyponatremia. Discussion: to our knowledge, this is the first reported case describing the successful use of oral urea for SIADH in a patient with concomitant Guillain-Barré syndrome, severe dysautonomia, and pheochromocytoma, supporting its role as an effective and safe therapeutic option when conventional treatments are limited or ineffective.
2026-08-21 | Case Report: Anti-GQ1b antibody-positive overlap syndrome: a pediatric case involving the brainstem, spinal cord, and peripheral nerves.
Disorders associated with anti-GQ1b antibodies predominantly encompass Bickerstaff brainstem encephalitis (BBE), Guillain-Barré syndrome (GBS), and Miller Fisher syndrome. Concurrent presentation of BBE, GBS, and acute transverse myelitis is exceptionally rare and presents significant diagnostic and therapeutic challenges. This report describes an 8-year-old boy who exhibited clinical features consistent with all three conditions, including impaired consciousness, ophthalmoplegia, ataxia, and limb weakness. Laboratory investigations revealed positive serum anti-GQ1b IgG antibodies, elevated cerebrospinal fluid protein levels with mild lymphocytic pleocytosis, and neurophysiological findings indicative of peripheral nerve demyelination. Magnetic resonance imaging of the brain and spinal cord demonstrated evidence of brainstem encephalitis and extensive spinal cord involvement. Following treatment with intravenous immunoglobulin and corticosteroid pulse therapy, marked neurological improvement was observed, and follow-up evaluations demonstrated favorable resolution of radiological abnormalities. This case highlights that anti-GQ1b antibody-associated syndrome may simultaneously affect the brainstem, spinal cord, and peripheral nerves. Early recognition and prompt initiation of combined immunotherapy may be critical for optimizing clinical outcomes.
2026-07-31 | Pyruvate Kinase M2 Upregulation Is Associated With Guillain-Barré Syndrome Risk and Immune Dysregulation: Insights From Mendelian Randomization and the Experimental Autoimmune Neuritis Model.
This study aimed to investigate the potential involvement of pyruvate kinase M2 (PKM2) in the pathogenesis of Guillain-Barré syndrome (GBS). Mendelian randomization (MR) analysis was used to evaluate the causal association between PKM2 expression and GBS susceptibility, with mediation analysis performed to explore immune cell-mediated pathways. The association between PKM2 methylation and GBS risk was further examined using GoDMC mQTL data and GRT-qPCRWAS Data Hub profiling. To validate these findings experimentally, an experimental autoimmune neuritis (EAN) mouse model was established in male C57BL/6 mice (6-8 weeks) by immunization with P0180-199 peptide, with tissues collected at disease initiation (Day 8) and peak stage (Day 16). PKM2 expression dynamics, Th17/Treg (regulatory T cells) balance, and histopathological changes were assessed using, Western blot, immunohistochemistry, immunofluorescence, flow cytometry, and H&E/Luxol fast blue (LFB) staining. MR analysis revealed that elevated PKM2 expression in the tibial nerve was significantly associated with an increased risk of GBS (OR: 1.75-6.14, p < 0.05). In the EAN model, PKM2 expression in the sciatic nerve exhibited a time-dependent increase (p < 0.01), primarily localized to inflammatory infiltrates. Mechanistic studies demonstrated that PKM2 upregulation in CD4+ T cells was associated with promoted Th17 differentiation, as evidenced by the upregulation of IL-17a and RORγt (p < 0.05), concomitant with a reduction in Treg cells (p < 0.01). To further elucidate the upstream epigenetic regulation, the association between PKM2 methylation and GBS risk was investigated using GoDMC mQTL data. Among the four selected methylation sites, two-sample MR analyses indicated that cg24327132 were positively associated with GBS risk (p < 0.05). Furthermore, analysis of the GWAS Data Hub revealed that cg24327132 appeared to be preferentially hypomethylated in adaptive immune cells including regulatory T cells, CD4+ T cells, and B cells (Beta ≈ 0-0.05), visually distinct from innate immune populations (Beta ≈ 0.10-0.20), suggesting that perturbation of this hypomethylated state may dysregulate PKM2 expression and contribute to GBS susceptibility. PKM2 upregulation is associated with GBS risk and immune dysfunction. PKM2 methylation may represent a key regulatory mechanism underlying this association. PKM2 may represent a mechanism target warranting further therapeutic investigation.
cell therapies
2026-09-18 | Case Report: Gait training using a wearable ankle-exoskeleton in a pediatric patient with Guillain-Barré syndrome.
Guillain-Barré syndrome (GBS) is an acute inflammatory demyelinating polyradiculoneuropathy that can lead to severe gait impairment and functional limitations in pediatric patients. Although conventional physiotherapy (CT) is the standard of care, recovery is often prolonged and characterized by persistent deficits in strength and motor control. Wearable ankle-exoskeletons have emerged as a potential adjunctive tool for task-specific gait training; however, their application in pediatric GBS remains largely unexplored. The aim of this single case report was to describe the clinical application of a structured gait training program using the Biomotum SPARK® wearable ankle-exoskeleton (SPARK®) combined with CT in a pediatric patient with GBS. Discrete variations in muscle strength, spatiotemporal parameters, pelvic kinematics, and muscle activation patterns were recorded between baseline (T0) and post-intervention (T2) assessments. Clinically, manual muscle testing scores suggested localized gains, particularly in bilateral hip abductors (moving from 3/5 to 4/5). Instrumented gait analysis indicated a baseline cadence variation from 101.7 to 108.5 steps/min, alongside a displacement of the gait symmetry index from 1.17% to 0.67%. Pelvic kinematic profiles suggested a trend toward alignment with normative reference bands, notably in pelvic obliquity and right pelvic rotation. Furthermore, surface electromyography recordings suggested localized modifications at T2, characterized by a lower envelope amplitude in the right gastrocnemius medialis activation pattern during the swing-phase (60%-100%) and an increase in amplitude within the normative activation periods of the left tibialis anterior. This single case report describes the clinical application of an integrated gait training protocol using the SPARK®, which was well-tolerated by the pediatric patient during the recovery-phase of GBS. However, these preliminary observations cannot be generalized or attributed solely to the wearable ankle-exoskeleton, as they likely reflect the combined, synergistic influence of spontaneous neurological recovery, conventional rehabilitation, motor learning, and increased walking exposure. Further controlled studies are necessary to evaluate the potential role and efficacy of wearable ankle-exoskeletons in pediatric GBS rehabilitation.
2026-08-20 | Clinical Outcomes of Double Filtration Plasmapheresis in Guillain-Barré Syndrome: A Single-Center Retrospective Study.
Guillain-Barré syndrome (GBS) is an acute immune-mediated peripheral neuropathy for which therapeutic apheresis is an established treatment option. Various treatment modalities, including double filtration plasmapheresis (DFPP), are widely used in clinical practice; however, real-world data on their clinical outcomes and adjunctive treatment strategies remain limited. We retrospectively analyzed 43 patients with GBS treated at a single tertiary center between June 2018 and October 2024, including 36 patients who received DFPP-containing regimens and 7 who received IVIG alone. Short-term functional outcomes were assessed using the modified Rankin scale (mRS) and Hughes functional grading scale (HFGS) at hospital admission before treatment and after completion of inpatient treatment. Changes in immunoglobulin and complement levels were evaluated in patients receiving DFPP. Exploratory analyses compared functional score changes across different treatment regimens. At hospital discharge, mRS and HFGS scores were significantly lower than baseline in patients receiving DFPP alone, DFPP combined with intravenous methylprednisolone, or IVIG alone. No significant differences in changes in functional scores were observed between the DFPP-alone and IVIG-alone groups or between the DFPP-alone and DFPP-plus-corticosteroid groups. DFPP significantly reduced serum immunoglobulin and complement levels; however, the percentage reductions in IgG, IgA, and IgM were not significantly correlated with short-term changes in mRS or HFGS scores. In this real-world cohort, DFPP-containing treatment was associated with short-term improvement in functional scores from hospital admission to hospital discharge. No statistically significant difference in short-term functional improvement was detected between the DFPP-alone and DFPP-plus-IVMP groups. However, the small sample size, heterogeneous treatment regimens, and lack of long-term follow-up preclude conclusions regarding sustained or comparative efficacy.
2026-07-31 | Case Report: Guillain-Barré syndrome mimicking acute brainstem stroke with severe autonomic dysfunction-complete recovery after early plasma exchange.
Acute onset of bilateral ptosis, bulbar palsy, and quadriparesis typically raises suspicion for brainstem infarction. However, when neuroimaging is unrevealing, immune-mediated neuropathies such as Guillain-Barré syndrome (GBS) should be considered. This case highlights the diagnostic challenge and therapeutic response in a seronegative, rapidly progressive GBS variant with severe autonomic involvement. We report a 57-year-old previously healthy man who presented with acute right-sided weakness and dysarthria, progressing over 36 hours to bilateral ptosis, complete ophthalmoplegia, dilated pupils, bulbar palsy, flaccid quadriparesis, urinary retention, and paralytic ileus. Initial brain MRI-DWI was negative. CSF showed no albuminocytologic dissociation. Anti-ganglioside antibodies and neuromuscular junction antibodies were negative. Electromyography revealed motor-predominant polyneuropathy with sympathetic skin response abnormalities. A diagnosis of atypical GBS with severe autonomic involvement was made. Plasma exchange was initiated at 40 hours after onset, followed by a second session on day 5. The patient improved dramatically, walked independently by day 8, was discharged on day 15, and achieved complete recovery at 1 month. This case demonstrates that GBS can present as an acute brainstem stroke mimic with severe ileus and urinary retention, even in the absence of CSF abnormalities or detectable autoantibodies. Early plasma exchange may result in complete neurological recovery. Therefore, clinicians should maintain a high clinical suspicion for immune-mediated neuropathies in patients presenting with rapidly progressive stroke mimics accompanied by autonomic dysfunction.
2026-07-30 | Robot-assisted gait training using a robotic exoskeleton during inpatient rehabilitation in acute Guillain-Barré Syndrome.
A woman in her early 60s with acute Guillain-Barré syndrome (GBS) developed rapidly progressive tetraparesis and respiratory failure requiring non-invasive ventilation. Following intravenous immunoglobulin and medical stabilisation, she entered inpatient rehabilitation with severe weakness, poor truncal control and inability to ambulate. Despite intensive conventional therapy, early gait training was limited. Exoskeleton-based robot-assisted gait training (RAGT) using the Hybrid Assistive Limb (HAL; Cyberdyne Inc, Tsukuba, Japan) was introduced during inpatient rehabilitation as an adjunct to standard therapy. The patient completed 10 HAL sessions over a 15-day period without adverse events. During this time, progressive improvements in ambulatory distance and functional independence were observed. By completion of HAL training, she was able to ambulate 50 m with a walking stick and minimal assistance. She subsequently continued conventional rehabilitation and achieved independent ambulation by discharge. This case suggests that HAL-based RAGT may be a feasible adjunct to inpatient rehabilitation in medically stable patients with acute GBS. The intervention was well tolerated in this patient. Further studies are required to establish patient-selection criteria, optimal timing and the effectiveness of exoskeleton-assisted gait training in GBS.
2026-07-11 | Impact of Gut Microbiota Dysbiosis in Treatment Outcomes of Guillain-Barré Syndrome.
The gut-microbiota plays a significant role in neuro-autoimmune diseases, like Guillain-Barré syndrome (GBS), a post-infectious disorder of the peripheral nervous system (PNS). By altering host immunity, gut dysbiosis may impact the standard therapeutic efficacy of intravenous immunoglobulin (IVIg) and plasma exchange (PE) and thereby, disease progression in GBS. In this study, we investigated the impact of gut-microbiota diversity on therapeutic outcomes of IVIg and PE in patients with GBS. We enrolled 60 patients with GBS categorized into three treatment groups: IVIg-treated, PE, and supportive-care along with 60 age-sex-matched healthy controls from Bangladesh. Fecal microbial DNA was extracted at different timepoints and sequenced. Clinical and sequenced data were analyzed using the Qiime2-Dada2 pipeline. Gut-microbial diversity significantly differed in patients with GBS before and after treatment (Shannon: p = 0.037; Evenness: p = 0.012), particularly in IVIg-treated patients, showing significant changes after 6-month treatment (Shannon: p = 0.034; Evenness: p = 0.011). Beta diversity indicated microbiota restoration in IVIg-treated patients toward a healthy state after treatment (p ≤ 0.001). Phylum Actinobacteriota (p = 0.026), genera Bifidobacterium (p = 0.006), and Enterococcus (p ≤ 0.0001) were relatively abundant in severe patients. Mechanically ventilated patients showed significant gut-microbial diversity (Unweighted-UniFrac; p ≤ 0.001). Biomarker analysis identified a higher abundance of Eubacterium, Bacteroides, Escherichia-Shigella, and Actinomyces in GBS patients. Our exploratory study indicates that gut microbiota dysbiosis is associated with GBS severity and IVIg-treatment outcomes. IVIg-treatment promoted partial restoration of microbial diversity, suggesting a potential immunomodulatory effect mediated through the microbiota. Further studies using meta-transcriptomics are warranted to define functional consequences of microbial shifts in treatment responses of GBS.
antibodies
2026-09-30 | Efgartigimod for Guillain-Barré syndrome: rationale, clinical evidence, and future perspectives.
Guillain-Barré syndrome (GBS) is an acute immune-mediated peripheral neuropathy characterized by rapidly progressive symmetric limb weakness and diminished tendon reflexes, which may be complicated by respiratory muscle paralysis in severe cases. Current first-line treatments primarily consist of intravenous immunoglobulin (IVIg) and plasma exchange (PE), but approximately 20% of patients have an incomplete response to standard therapies. Additionally, issues such as limited supply of blood products, adverse reactions, and contraindications may limit conventional treatments. Efgartigimod alfa is an engineered human IgG1 Fc fragment that targets the neonatal Fc receptor (FcRn) and competitively inhibits FcRn-mediated lgG recycling, thereby promoting the lysosomal degradation of circulating IgG, including pathogenic IgG autoantibodies, and reducing serum IgG levels. Intravenous efgartigimod alfa is approved for AChR antibody-positive generalized myasthenia gravis (gMG), whereas the U.S. approval for chronic inflammatory demyelinating polyneuropathy (CIDP) applies to the subcutaneous efgartigimod alfa/hyaluronidase co-formulation. Neither formulation is currently approved for GBS. Because IgG-mediated autoimmunity contributes to the pathogenesis of a subset of GBS, FcRn blockade provides a biologically plausible therapeutic strategy; however, its relevance may vary according to the underlying immunopathology. This narrative review summarizes the mechanistic rationale, preliminary clinical evidence, and available safety observations regarding efgartigimod in GBS, critically evaluates the limitations of the current evidence, and discusses unresolved questions and priorities for future research.
2026-09-25 | Acute Management of Guillain-Barré Syndrome: A Narrative Review.
Guillain-Barré syndrome (GBS) is a rapidly progressive immune-mediated polyradiculoneuropathy that can cause respiratory failure, autonomic dysfunction, and significant long-term disability. This narrative review examines the acute management of GBS, including supportive care, established immunotherapies, and emerging treatment strategies. Early recognition and close monitoring of respiratory and autonomic function remain essential, particularly during the progressive phase of disease. Intravenous immunoglobulin (IVIg) and plasma exchange remain the primary disease-modifying treatments and have similar overall efficacy, although both primarily accelerate recovery rather than prevent ongoing nerve injury. Their limitations, including treatment-related fluctuations, adverse effects, cost, supply limitations, and the logistical challenges of plasma exchange, highlight the need for more effective therapies. Emerging treatments are increasingly targeting specific mechanisms involved in GBS pathophysiology. Although the C5 inhibitor eculizumab failed to improve outcomes in a phase 3 trial, early results with the upstream C1q inhibitor ANX005 suggest that earlier complement inhibition may reduce nerve injury and improve functional outcomes. Other investigational approaches include IgG-degrading enzymes such as imlifidase, FcRn inhibitors such as efgartigimod, regulatory T-cell therapies, and regenerative strategies. However, most of these treatments lack adequately powered randomized clinical trial data. Important gaps also remain in subtype-specific treatment, nerve regeneration, long-term rehabilitation, treatment-related fluctuations, and access to care. Future research should focus on more targeted and individualized therapies that address both immune-mediated injury and subsequent nerve damage.
2026-09-20 | Pan-Neurofascin Antibody-Associated Nodopathy: A Critical Guillain-Barré Syndrome Mimic in the Differential Diagnosis-Report of Two Cases.
Guillain-Barré syndrome (GBS) is an acute autoimmune polyradiculoneuropathy typically characterized by an ascending sensorimotor deficit with potential involvement of bulbar and respiratory muscles that may necessitate intensive care admission and mechanical ventilation. Standard treatment includes supportive care, management of complications such as weakness, immobility, respiratory failure, autonomic dysfunction and pain, along with early initiation of immunotherapy-either intravenous immunoglobulin (IVIg) or plasma exchange (PE). However, lack of significant clinical improvement following immunotherapy should prompt consideration of alternative diagnoses, including pan-neurofascin antibody-positive autoimmune nodopathy (panNF + AN). In this report, we present two patients presenting with a severe GBS-like neuropathy. Initial treatment with IVIg resulted in either no response or only transient, mild improvement, followed by rapid clinical deterioration to near-complete tetraplegia, respiratory failure, and autonomic and cranial nerve involvement. Both patients were unresponsive to further treatment with a second course of IVIg, PE and corticosteroids. Subsequent diagnostic evaluation revealed the presence of pan-neurofascin antibodies, confirming panNF + AN. This prompted initiation of treatment with rituximab, which resulted in sustained and complete clinical recovery in both cases. A transient or mild clinical response-or an initial lack of response-to standard GBS-treatment followed by rapid and severe deterioration in cases initially presenting as GBS should be considered a red flag warranting evaluation for AN-associated antibodies. Recognition of this important GBS mimic is critical, as it requires an alternative treatment approach with rituximab, which has been associated excellent clinical outcomes.
2026-09-01 | Causal relationship between immune factors and Guillain-Barré syndrome: A Mendelian randomization study.
Guillain-Barré syndrome (GBS) is an immune-mediated polyneurogenic disorder that is strongly correlated with immune factors. However, causal relationships between these factors remain unclear. We used 2-sample Mendelian randomization (MR) and inverse MR analysis. Immune factors were used as the outcome for GBS exposure. Cochrane Q test was used to detect heterogeneity. Simultaneously, the MR-Egger intercept test and MR-Pleiotropy Residual Sum and Outlier tests were used to check for horizontal pleiotropy. MR Steiger was used to estimate the direction of causal inference when the instrumental variables were insufficient in inverse MR. Eighteen immune traits and 1 inflammatory protein were identified as causally involved in the risk of GBS. Reverse MR revealed that GBS was correlated with the levels of eleven immune traits. The sensitivity analyses did not identify any potential heterogeneity or horizontal pleiotropy. Steiger did not find any evidence of reverse causation. We used 2-sample MR to investigate the causal relationship between immune factors and GBS, and our results provide clues for further research.
2026-08-26 | Arboviral infections of the central nervous system: Mechanisms of invasion and long-term consequences.
Arboviruses are a diverse group of vector-borne viruses that cause significant global morbidity and mortality. Beyond classical systemic and febrile symptoms, many arboviruses can induce a spectrum of neurological complications, ranging from mild encephalopathy to severe neuroinvasive disease. This review summarizes current knowledge on major arboviruses from the Flaviviridae, Togaviridae, Peribunyaviridae, and Reoviridae families, emphasizing mechanisms of CNS invasion, neurological manifestations, and relevant case studies or outbreaks. Mechanisms of central nervous system (CNS) invasion are highlighted, including direct viral neurotropism, blood-brain barrier crossing such as Trojan horse-mediated leukocyte trafficking and immune-mediated neuropathology. Clinical syndromes, including encephalitis, myelitis, Guillain-Barré syndrome, and movement disorders, are discussed alongside relevant case studies and outbreak reports. This review provides an integrated perspective on arbovirus-induced neurological disease for clinicians, researchers, and public health professionals.
proteins
2026-06-12 | A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy.
Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are immune-mediated inflammatory neuropathies characterized by T cell- and/or autoantibody-driven injury to peripheral nerves. Although intravenous immunoglobulin (IVIg) is effective in both conditions, its use is limited by high dosing requirements, supply constraints, and manufacturing complexity. NVG-2089 is a recombinant IgG1 Fc-domain protein engineered to selectively agonize type II Fc receptors, promoting anti-inflammatory signaling through expansion of regulatory T cells (Tregs) and upregulation of the inhibitory Fcγ receptor FcγRIIB. Its efficacy in immune complex-mediated disease and T cell-driven neuroinflammation prompted evaluation of its therapeutic potential in an animal model of inflammatory demyelinating neuropathy. We conducted a randomized, blinded preclinical study in the spontaneous autoimmune peripheral polyneuropathy model, a well-established murine model of inflammatory demyelinating neuropathy. Animals were treated with NVG-2089, high-dose IVIg, or vehicle. Outcomes included behavioral performance, nerve electrophysiology, peripheral nerve morphometrics, immunohistochemistry, and flow cytometric immunophenotyping. Both NVG-2089 and IVIg stabilized motor and sensory performance, preserved compound muscle action potential (CMAP) amplitudes, and attenuated demyelination-associated prolongation of distal latency and CMAP duration. Morphometric analyses demonstrated preservation of myelinated fiber density and normalization of g-ratio distributions in both treatment groups. Immunophenotyping indicated an expansion of functionally activated CD25+CD39+ Tregs in the spleen, along with increased FcγRIIB expression on B cells, monocytes, and dendritic cells across systemic and nerve-associated compartments, consistent with engagement of shared anti-inflammatory pathways. NVG-2089 demonstrated robust neuroprotective efficacy comparable to IVIg while requiring a substantially lower protein dose. These findings support NVG-2089 as a promising, dose-efficient alternative to IVIg for the treatment of inflammatory demyelinating neuropathies, including GBS and CIDP.
2026-05-08 | Varicella-zoster virus infection triggering GD3 antibody-positive variant Guillain-Barré syndrome: a case report and literature review.
Bilateral facial palsy variant Guillain-Barré syndrome (GBS) is a distinct clinical subtype. As an acute immune-mediated polyradiculoneuropathy often triggered by infections, varicella-zoster virus (VZV) is a rare yet significant precipitating factor for this variant. Anti-ganglioside antibodies, particularly anti-GD3, are involved in the pathogenesis of GBS, but their significance in VZV-associated bilateral facial palsy subtype remains incompletely elucidated. We report a 46-year-old female who developed acute bilateral facial palsy and limb sensory deficits following VZV infection. Serum anti-ganglioside testing confirmed GD3 IgG positivity, and cerebrospinal fluid analysis revealed albuminocytological dissociation. Nerve conduction studies supported a demyelinating polyneuropathy, and the patient showed significant improvement after intravenous immunoglobulin therapy. This case suggests that VZV may act as a potential trigger for GD3 antibody-positive variant GBS. Early immunotherapy may improve outcomes, emphasizing the need for systematic antibody testing in atypical presentations of this variant GBS. Further studies are required to clarify the pathophysiological role of GD3 antibodies in VZV-associated variant GBS.
2025-11-05 | Diagnostic and therapeutic potential of resolvin D1 in Guillain-Barré syndrome.
Most neuroimmune diseases are incurable and require lifelong immunotherapy, whereas Guillain-Barré syndrome (GBS), a peripheral nervous system autoimmune disorder, has a relatively favorable prognosis. Investigating the molecular disparities underlying recovery between GBS and other neuroimmune diseases may facilitate the development of innovative therapeutic strategies. This study explored the diagnostic and therapeutic potential of resolvin D1 (RvD1), a specialized pro-resolving mediator that promotes inflammation resolution and tissue regeneration, in GBS and its animal model experimental autoimmune neuritis (EAN). Serum RvD1 levels were measured in 218 participants from two cohorts, including healthy controls (HCs), GBS patients, and those with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), or stroke. The diagnostic accuracy was evaluated via the area under the receiver operating characteristic (ROC) curve (AUC). RvD1 was administered to EAN and experimental autoimmune encephalomyelitis (EAE, an MS animal model) to assess its therapeutic efficacy. Serum RvD1 was elevated in GBS patients, demonstrating high diagnostic accuracy in differentiating GBS patients from HCs (cohort 1: AUC 0.72; cohort 2: AUC 0.93), MS/NMOSD patients (cohort 1: AUC 0.83), and stroke patients (cohort 1: AUC 0.68). The RvD1 level continued to increase as GBS progressed and was positively correlated with disease severity, ventilator dependence, and axonal neuropathy. In EAN, RvD1 and its synthetase/receptor were upregulated in serum, spleen, and sciatic nerve, exhibiting tissue-specific inflammation resolution patterns across disease phases. RvD1 treatment promoted inflammation resolution in EAN, as evidenced by attenuated disease severity and autoimmune responses, with its therapeutic effect was translatable to EAE. RvD1 may serve as a biomarker for both diagnosing GBS and monitoring disease severity. It represents a potential immunotherapeutic agent for GBS and other neuroimmune disorders. Elucidating the molecules associated with recovery in patients with GBS may facilitate the discovery of novel therapeutic strategies for neuroimmune disorders.
2025-10-14 | Exacerbation of demyelinating polyneuropathy after adoptive cell therapy with tumour-infiltrating lymphocytes by metastatic melanoma.
Adoptive cell therapy (ACT) with tumour-infiltrating lymphocytes (TIL) is an effective personalised immunotherapy for patients with advanced pretreated melanoma. For TIL-ACT, tumour-specific T cells are expanded from excised tumour samples and stimulated in cell culture with interleukin-2 (IL-2). The resulting autologous tumour-infiltrating lymphocytes are reinfused to the patient after a non-myeloablative lymphodepleting chemotherapy with cyclophosphamide and fludarabine. Thereafter, activation of tumour-infiltrating lymphocytes in the patient is supported by the administration of high-dose IL-2. Although effective, there is a need for enhancement of TIL-ACT in terms of effectiveness and toxicity. Most of the toxicity in this multistep, complex treatment regimen is due to the preparative chemotherapy and high-dose IL-2 treatment. At University Hospital Basel, we are currently evaluating an experimental approach of TIL-ACT in which we replace high-dose IL-2 by in vivo tumour-infiltrating lymphocyte activation with ANV419, a novel antibody-cytokine fusion protein consisting of IL-2 fused to an anti-IL-2 monoclonal antibody, in an ongoing phase I trial (BaseTIL-03M). The primary endpoint of the study is safety. We herein describe the case of a patient included in the BaseTIL-03M trial with chronic inflammatory demyelinating polyneuropathy who received TIL-ACT with ANV419 and developed an acute polyneuropathy of Guillain-Barré syndrome.
2025-08-24 | Design of Hyperglycosylated Zika Virus E Proteins that Focus Antibody Recognition on the Complex E Dimer Epitope.
Zika virus (ZIKV) and dengue virus serotypes 1-4 (DENV1-4) are flaviviruses spread by Aedes mosquitoes. ZIKV infection can cause Guillain-Barré syndrome and microcephaly, while severe dengue can lead to hemorrhagic fever and death. DENV infection of ZIKV-immune individuals is linked to severe clinical outcomes due to antibody-dependent enhancement (ADE) of infection. Thus, the development of broadly protective vaccines is an important objective. We focus on the E dimer epitope (EDE) of ZIKV, which is targeted by broadly neutralizing antibodies that protect against ZIKV and DENV1-4. We engineered ZIKV E dimer variants containing non-native asparagine-linked glycosylation sites to block antibody responses to regions outside the EDE using a structure-based iterative design approach. One candidate, SC30m53, bound EDE mAbs but not other mAbs and induced a potently neutralizing response against ZIKV and moderately cross-neutralizing responses against DENV1-3 in mice. These findings suggest that hyperglycosylation provides a promising approach to focusing the immune response on key epitopes.
other
2026-07-17 | COVID-19 mRNA Vaccination Reduces Guillain-Barré Syndrome Risk: Evidence from a Large Longitudinal Cohort Study.
The association between COVID-19 vaccination and Guillain-Barré syndrome (GBS) has been previously investigated with inconsistent results, largely due to limited data and lack of concurrent controls. To address this problem, a large longitudinal cohort study was conducted using National COVID Cohort Collaborative (N3C) data. While COVID-19 infection was associated with increased GBS occurrence, COVID-19 vaccination was associated with significantly reduced GBS risk relative to unexposed (unvaccinated and uninfected) control, corresponding to a 61% lower 30-day risk (incidence risk ratio: IRR = 0.39, P < 0.01), consistent with multivariable Cox regression showing a similar reduction (adjusted hazard ratio: aHR = 0.41, P < 0.01). This protective association was observed only among recipients of mRNA vaccines (BNT162b2: IRR = 0.38, P < 0.01; mRNA-1273: IRR = 0.24, P < 0.01), but not among recipients of adenoviral-vector vaccines (IRR = 1.38, P > 0.05). Prior COVID-19 vaccination also reduced infection-associated GBS risk. Additional factors associated with GBS risk included sex, vaccine dose, and pre-existing comorbidities such as stroke, neurological disorders, and autoimmune diseases. Overall, our N3C large-scale study provides evidence that COVID-19 mRNA vaccination reduces GBS risk, supporting the safety profile of mRNA vaccines and warranting further mechanistic investigation.
2026-04-01 | The EGR1/ZFP36 axis governs glycosphingolipid metabolic reprogramming in monocyte-derived macrophages in guillain-barré syndrome.
Guillain-Barré syndrome (GBS) is an immune-mediated demyelinating disorder of peripheral nerves with an unclear pathogenesis. This study integrated GBS clinical single-cell data with EAN model transcriptome data, establishing in vivo and in vitro experimental systems to reveal, for the first time, a novel mechanism involving EGR1-ZFP36 and its mediated metabolic reprogramming in GBS pathogenesis. Findings indicated that the transcription factor EGR1 and its predicted target gene ZFP36 were downregulated in both GBS patients and EAN rats. Molecular interaction validation confirmed that EGR1 directly bound to and activated the transcription of ZFP36. Transcriptomic and metabolomic analyses revealed that the EGR1/ZFP36 axis specifically drove macrophage reprogramming toward a glycosphingolipid metabolism-active state. Functionally, EGR1 overexpression promoted the expression of key glycosphingolipid metabolism genes (HEXA, HEXB) by upregulating ZFP36, thereby facilitating polarization toward the anti-inflammatory M2 phenotype. Animal experiments further demonstrated that EGR1 overexpression improved motor function and ameliorated myelin damage in the EAN model, with this protective effect being mediated by ZFP36. Collectively, this study reveals that EGR1 drives glycosphingolipid metabolic reprogramming in monocyte-derived macrophages by transcriptionally activating ZFP36, thereby regulating cellular polarization and participating in the demyelination process of GBS. This discovery not only provides a novel perspective on understanding the immunometabolic mechanisms of GBS but also lays a theoretical foundation for potential therapeutic strategies targeting the EGR1-ZFP36-glycosphingolipid metabolism axis.
2025-12-30 | A Review of Cutaneous Viral Infections and Their Potential Role in Neurologic Diseases.
Background: Cutaneous viral infections, defined as viral pathogens that either primarily affect the skin (e.g., herpesviruses, enteroviruses) or frequently produce dermatologic manifestations despite systemic tropism (e.g., HIV, SARS-CoV-2), can trigger systemic inflammatory and neurotropic responses that extend their impact to the nervous system. A growing body of evidence suggests that viruses with dermatologic manifestations may play a significant role in the pathogenesis of neurologic disorders. Summary: Although individual viruses have been studied in isolation, the skin-brain axis in viral infections remains incompletely characterized. This review synthesizes existing knowledge and highlights gaps in understanding the mechanisms linking cutaneous viral infections to neurologic disease. We explore the principal mechanisms linking viral skin infections to central and peripheral nervous system damage, including direct neuroinvasion, immune-mediated injury, and vascular or endothelial dysfunction. Particular attention is given to herpesviruses, retroviruses, enteroviruses, and respiratory viruses, which have been associated with conditions such as dementia, multiple sclerosis, myelopathies, Guillain-Barré syndrome, and the post-acute neurologic sequelae of COVID-19. Furthermore, we discuss the role of neuroinflammation in viral-associated neurodegeneration and highlight emerging evidence supporting the recombinant zoster vaccine (Shingrix) as a potential modulator of neuroinflammatory processes and a protective factor against dementia. Conclusions: Cutaneous viral infections extend beyond local skin pathology, contributing to a broad spectrum of neurologic complications through intertwined infectious and inflammatory mechanisms. A clearer understanding of how peripheral viral activity shapes central nervous system vulnerability remains a major unmet need. A multidisciplinary approach integrating dermatologic and neurologic perspectives is essential for early recognition and prevention. While observational studies suggest that zoster vaccination may reduce viral reactivation and modulate neuroinflammatory pathways, definitive evidence of neuroprotection is still lacking. Future studies should clarify causal relationships, test mechanistic hypotheses regarding skin-brain immune crosstalk, and explore vaccine-mediated neuroprotection as a novel therapeutic strategy.
2025-10-28 | The Yin and Yang of Antibodies in Viral Infectious Diseases.
Antibodies are a cornerstone of the adaptive immune response, serving as key defenders against viral infections; however, they can also act as a double-edged sword, contributing to immune-mediated pathologies. This review advances a "Yin-Yang" framework to integrate the dual activities of antibodies. The protective 'Yin' functions are driven by high-affinity antibodies generated through processes like somatic hypermutation and class-switch recombination. These antibodies execute viral neutralization, activate the complement system, and engage Fc receptors (FcRs) to drive antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis. These mechanisms form the immunological basis of effective vaccines, which aim to elicit durable and functionally specialized antibody isotypes like IgG and mucosal IgA. Conversely, the pathogenic 'Yang' of the response can be detrimental. This includes antibody-dependent enhancement (ADE) of infection, notably observed with flaviviruses, and the development of autoimmunity through mechanisms like molecular mimicry and bystander activation, which can lead to conditions such as multiple sclerosis and Guillain-Barré Syndrome. The balance between protection and pathology is tipped by a confluence of factors. These include viral evasion strategies like antigenic mutation and glycan shielding, as well as host-based determinants such as genetic polymorphisms in FcRs, immune history, and the gut microbiome. Understanding these molecular determinants informs the rational design of next-generation interventions. Promising strategies, such as Fc-region glyco-engineering and the design of tolerogenic vaccines, aim to selectively promote protective functions while minimizing pathological risks, offering a clear path forward in combating viral threats.
2025-10-18 | A systematic review of CRISPR applications in demyelinating peripheral nervous system disorders.
This review evaluates CRISPR-based strategies for myelin regeneration in peripheral demyelinating disorders, with a focus on Guillain - Barré syndrome (GBS) and Charcot - Marie - Tooth disease type 1A (CMT1A). It aims to identify current therapeutic approaches, delivery systems, and gaps in the literature. A systematic literature search was conducted across PubMed, Scopus, Web of Science, and Google Scholar for studies published from 2010 onward, following PRISMA guidelines. Study quality was assessed using OHAT and SYRCLE tools, and 14 articles met the inclusion criteria. In GBS, CRISPR interventions primarily targeted antiviral immune regulation (AXL, IFI6, IFNL2), inhibition of viral entry mechanisms (Integrin αvβ5, SPCS1), and Schwann cell repair. In CMT1A, therapeutic approaches focused on correcting PMP22 overexpression. Lentiviral transduction was the most frequently used delivery method, with no major adverse effects reported. However, most studies were in vitro, and only two were in vivo, highlighting the need for further validation in animal models. CRISPR technology shows considerable potential for addressing peripheral nerve demyelination through precise genetic modifications that may enhance Schwann cell function and support myelin repair. Nevertheless, the field remains at an early discovery stage, with no near-term clinical applicability demonstrated.
small molecules
2026-09-11 | P2X7 Receptor in Rare Diseases: Shared Molecular Mechanisms and Therapeutic Implications.
Rare diseases (RDs) are individually uncommon but collectively affect a large global population, and the vast majority still lack effective disease-modifying therapies. With advances in genomics and data-sharing platforms, research has increasingly shifted from a single-disease perspective to the search for convergent molecular pathways that might be shared across clinically distinct entities. In this context, the purinergic P2X7 receptor (P2X7R) has emerged as a putative "shared molecular platform" due to its central role in inflammation amplification, cell death and immune regulation. P2X7R is an ATP-gated ion channel with unique structural and functional features: under high extracellular ATP, it not only forms a non-selective cation channel but can also dilate into a "large pore" permeable to macromolecules, thereby triggering Ca2+overload, NLRP3 inflammasome assembly, reactive oxygen species (ROS) production and apoptotic/necrotic-like cell death. This review briefly outlines the epidemiology of RDs and the structural-functional characteristics of P2X7R, then systematically summarizes current evidence linking P2X7R to multiple rare diseases, including Charcot-Marie-Tooth disease, Guillain-Barré syndrome, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and selected inflammatory and metabolic RDs (CAPS, familial Mediterranean fever, Systemic sclerosis, Dravet syndrome and Gaucher disease). By comparing P2X7R expression and functional alterations, downstream signaling pathways and pharmacological data from animal models across these conditions, we propose that a P2X7R-dependent network centered on a "Ca2+-NLRP3-inflammation/cell death axis" may constitute a common pathogenic backbone for diverse RDs. At the same time, disease-specific spatiotemporal expression patterns of P2X7R in central vs peripheral nervous systems and in immune vs target organ cells confer marked context dependence and "double-edged sword" properties. Finally, we discuss opportunities and challenges for P2X7R-targeted strategies, including the impact of disease stage and sex differences on therapeutic efficacy, and key bottlenecks in translating preclinical findings into clinical benefit. A deeper understanding of both shared and disease-specific roles of P2X7R may provide a conceptual framework and therapeutic entry point for precision stratification and multi-target interventions in rare diseases.
2026-09-08 | A Rare Atypical Cardiac-Arrest Onset of Fulminant Systemic Lupus Erythematosus with Multiorgan Failure, Myocarditis, and AMAN- Variant Guillain-Barré Syndrome Successfully Treated with Multimodal Immunotherapy.
This report highlights a rare, catastrophic presentation of Systemic Lupus Erythematosus (SLE) manifesting as sudden cardiovascular collapse in a patient with no prior autoimmune history. The case is particularly novel due to the concurrent development of the Acute Motor Axonal Neuropathy (AMAN) variant of Guillain-Barré Syndrome (GBS) alongside multiorgan failure, mimicking septic and cardiogenic shock. A 49-year-old woman suffered an out-of-hospital cardiac arrest following acute gastroenteritis, characterized by recurrent ventricular fibrillation and tachycardia. She rapidly developed multiorgan failure, including severe myocardial dysfunction (EF 29%), acute kidney injury, metabolic acidosis, and altered consciousness. While the initial presentation suggested sepsis, subsequent testing revealed positive antinuclear antibodies, lupus anticoagulant, and hypocomplementemia, meeting ACR/EULAR criteria for SLE. Electrophysiological studies for persistent weakness confirmed AMAN-type GBS. Following an aggressive multimodal immunotherapy regimen of corticosteroid pulses, Intravenous Immunoglobulin (IVIG), and rituximab, the patient achieved significant recovery of cardiac, renal, and neurological functions. This case demonstrates that SLE can present as a life-threatening "autoimmune storm" mimicking sepsis or primary heart failure. Early identification is vital in atypical critical illness, as aggressive immunotherapy can reverse even severe multiorgan dysfunction. Clinicians should consider autoimmune screening in cases of unexplained cardiac arrest and multiorgan failure to prevent diagnostic delays and improve outcomes.
2026-09-07 | [Oral urea in the management of inappropriate antidiuretic hormone secretion syndrome associated with Guillain-Barré syndrome, severe dysautonomia, and pheochromocytoma ‒ An exceptional clinical case].
Introduction and case report: we report the case of an 82-year-old man with pheochromocytoma and colon adenocarcinoma who developed rapidly progressive Guillain-Barré syndrome with severe dysautonomia following a recent SARS-CoV-2 infection. In this setting, he developed progressive hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH). Marked autonomic instability related to the coexistence of Guillain-Barré syndrome and pheochromocytoma limited conventional therapeutic options. After an inadequate response to fluid restriction and oral sodium chloride supplementation, oral urea therapy was initiated, resulting in a gradual and safe correction of serum sodium without significant adverse events. Normalization of serum sodium enabled completion of preoperative management and successful adrenalectomy and colon cancer surgery, without recurrence of hyponatremia. Discussion: to our knowledge, this is the first reported case describing the successful use of oral urea for SIADH in a patient with concomitant Guillain-Barré syndrome, severe dysautonomia, and pheochromocytoma, supporting its role as an effective and safe therapeutic option when conventional treatments are limited or ineffective.
2026-08-21 | Case Report: Anti-GQ1b antibody-positive overlap syndrome: a pediatric case involving the brainstem, spinal cord, and peripheral nerves.
Disorders associated with anti-GQ1b antibodies predominantly encompass Bickerstaff brainstem encephalitis (BBE), Guillain-Barré syndrome (GBS), and Miller Fisher syndrome. Concurrent presentation of BBE, GBS, and acute transverse myelitis is exceptionally rare and presents significant diagnostic and therapeutic challenges. This report describes an 8-year-old boy who exhibited clinical features consistent with all three conditions, including impaired consciousness, ophthalmoplegia, ataxia, and limb weakness. Laboratory investigations revealed positive serum anti-GQ1b IgG antibodies, elevated cerebrospinal fluid protein levels with mild lymphocytic pleocytosis, and neurophysiological findings indicative of peripheral nerve demyelination. Magnetic resonance imaging of the brain and spinal cord demonstrated evidence of brainstem encephalitis and extensive spinal cord involvement. Following treatment with intravenous immunoglobulin and corticosteroid pulse therapy, marked neurological improvement was observed, and follow-up evaluations demonstrated favorable resolution of radiological abnormalities. This case highlights that anti-GQ1b antibody-associated syndrome may simultaneously affect the brainstem, spinal cord, and peripheral nerves. Early recognition and prompt initiation of combined immunotherapy may be critical for optimizing clinical outcomes.
2026-07-31 | Pyruvate Kinase M2 Upregulation Is Associated With Guillain-Barré Syndrome Risk and Immune Dysregulation: Insights From Mendelian Randomization and the Experimental Autoimmune Neuritis Model.
This study aimed to investigate the potential involvement of pyruvate kinase M2 (PKM2) in the pathogenesis of Guillain-Barré syndrome (GBS). Mendelian randomization (MR) analysis was used to evaluate the causal association between PKM2 expression and GBS susceptibility, with mediation analysis performed to explore immune cell-mediated pathways. The association between PKM2 methylation and GBS risk was further examined using GoDMC mQTL data and GRT-qPCRWAS Data Hub profiling. To validate these findings experimentally, an experimental autoimmune neuritis (EAN) mouse model was established in male C57BL/6 mice (6-8 weeks) by immunization with P0180-199 peptide, with tissues collected at disease initiation (Day 8) and peak stage (Day 16). PKM2 expression dynamics, Th17/Treg (regulatory T cells) balance, and histopathological changes were assessed using, Western blot, immunohistochemistry, immunofluorescence, flow cytometry, and H&E/Luxol fast blue (LFB) staining. MR analysis revealed that elevated PKM2 expression in the tibial nerve was significantly associated with an increased risk of GBS (OR: 1.75-6.14, p < 0.05). In the EAN model, PKM2 expression in the sciatic nerve exhibited a time-dependent increase (p < 0.01), primarily localized to inflammatory infiltrates. Mechanistic studies demonstrated that PKM2 upregulation in CD4+ T cells was associated with promoted Th17 differentiation, as evidenced by the upregulation of IL-17a and RORγt (p < 0.05), concomitant with a reduction in Treg cells (p < 0.01). To further elucidate the upstream epigenetic regulation, the association between PKM2 methylation and GBS risk was investigated using GoDMC mQTL data. Among the four selected methylation sites, two-sample MR analyses indicated that cg24327132 were positively associated with GBS risk (p < 0.05). Furthermore, analysis of the GWAS Data Hub revealed that cg24327132 appeared to be preferentially hypomethylated in adaptive immune cells including regulatory T cells, CD4+ T cells, and B cells (Beta ≈ 0-0.05), visually distinct from innate immune populations (Beta ≈ 0.10-0.20), suggesting that perturbation of this hypomethylated state may dysregulate PKM2 expression and contribute to GBS susceptibility. PKM2 upregulation is associated with GBS risk and immune dysfunction. PKM2 methylation may represent a key regulatory mechanism underlying this association. PKM2 may represent a mechanism target warranting further therapeutic investigation.
cell therapies
2026-09-18 | Case Report: Gait training using a wearable ankle-exoskeleton in a pediatric patient with Guillain-Barré syndrome.
Guillain-Barré syndrome (GBS) is an acute inflammatory demyelinating polyradiculoneuropathy that can lead to severe gait impairment and functional limitations in pediatric patients. Although conventional physiotherapy (CT) is the standard of care, recovery is often prolonged and characterized by persistent deficits in strength and motor control. Wearable ankle-exoskeletons have emerged as a potential adjunctive tool for task-specific gait training; however, their application in pediatric GBS remains largely unexplored. The aim of this single case report was to describe the clinical application of a structured gait training program using the Biomotum SPARK® wearable ankle-exoskeleton (SPARK®) combined with CT in a pediatric patient with GBS. Discrete variations in muscle strength, spatiotemporal parameters, pelvic kinematics, and muscle activation patterns were recorded between baseline (T0) and post-intervention (T2) assessments. Clinically, manual muscle testing scores suggested localized gains, particularly in bilateral hip abductors (moving from 3/5 to 4/5). Instrumented gait analysis indicated a baseline cadence variation from 101.7 to 108.5 steps/min, alongside a displacement of the gait symmetry index from 1.17% to 0.67%. Pelvic kinematic profiles suggested a trend toward alignment with normative reference bands, notably in pelvic obliquity and right pelvic rotation. Furthermore, surface electromyography recordings suggested localized modifications at T2, characterized by a lower envelope amplitude in the right gastrocnemius medialis activation pattern during the swing-phase (60%-100%) and an increase in amplitude within the normative activation periods of the left tibialis anterior. This single case report describes the clinical application of an integrated gait training protocol using the SPARK®, which was well-tolerated by the pediatric patient during the recovery-phase of GBS. However, these preliminary observations cannot be generalized or attributed solely to the wearable ankle-exoskeleton, as they likely reflect the combined, synergistic influence of spontaneous neurological recovery, conventional rehabilitation, motor learning, and increased walking exposure. Further controlled studies are necessary to evaluate the potential role and efficacy of wearable ankle-exoskeletons in pediatric GBS rehabilitation.
2026-08-20 | Clinical Outcomes of Double Filtration Plasmapheresis in Guillain-Barré Syndrome: A Single-Center Retrospective Study.
Guillain-Barré syndrome (GBS) is an acute immune-mediated peripheral neuropathy for which therapeutic apheresis is an established treatment option. Various treatment modalities, including double filtration plasmapheresis (DFPP), are widely used in clinical practice; however, real-world data on their clinical outcomes and adjunctive treatment strategies remain limited. We retrospectively analyzed 43 patients with GBS treated at a single tertiary center between June 2018 and October 2024, including 36 patients who received DFPP-containing regimens and 7 who received IVIG alone. Short-term functional outcomes were assessed using the modified Rankin scale (mRS) and Hughes functional grading scale (HFGS) at hospital admission before treatment and after completion of inpatient treatment. Changes in immunoglobulin and complement levels were evaluated in patients receiving DFPP. Exploratory analyses compared functional score changes across different treatment regimens. At hospital discharge, mRS and HFGS scores were significantly lower than baseline in patients receiving DFPP alone, DFPP combined with intravenous methylprednisolone, or IVIG alone. No significant differences in changes in functional scores were observed between the DFPP-alone and IVIG-alone groups or between the DFPP-alone and DFPP-plus-corticosteroid groups. DFPP significantly reduced serum immunoglobulin and complement levels; however, the percentage reductions in IgG, IgA, and IgM were not significantly correlated with short-term changes in mRS or HFGS scores. In this real-world cohort, DFPP-containing treatment was associated with short-term improvement in functional scores from hospital admission to hospital discharge. No statistically significant difference in short-term functional improvement was detected between the DFPP-alone and DFPP-plus-IVMP groups. However, the small sample size, heterogeneous treatment regimens, and lack of long-term follow-up preclude conclusions regarding sustained or comparative efficacy.
2026-07-31 | Case Report: Guillain-Barré syndrome mimicking acute brainstem stroke with severe autonomic dysfunction-complete recovery after early plasma exchange.
Acute onset of bilateral ptosis, bulbar palsy, and quadriparesis typically raises suspicion for brainstem infarction. However, when neuroimaging is unrevealing, immune-mediated neuropathies such as Guillain-Barré syndrome (GBS) should be considered. This case highlights the diagnostic challenge and therapeutic response in a seronegative, rapidly progressive GBS variant with severe autonomic involvement. We report a 57-year-old previously healthy man who presented with acute right-sided weakness and dysarthria, progressing over 36 hours to bilateral ptosis, complete ophthalmoplegia, dilated pupils, bulbar palsy, flaccid quadriparesis, urinary retention, and paralytic ileus. Initial brain MRI-DWI was negative. CSF showed no albuminocytologic dissociation. Anti-ganglioside antibodies and neuromuscular junction antibodies were negative. Electromyography revealed motor-predominant polyneuropathy with sympathetic skin response abnormalities. A diagnosis of atypical GBS with severe autonomic involvement was made. Plasma exchange was initiated at 40 hours after onset, followed by a second session on day 5. The patient improved dramatically, walked independently by day 8, was discharged on day 15, and achieved complete recovery at 1 month. This case demonstrates that GBS can present as an acute brainstem stroke mimic with severe ileus and urinary retention, even in the absence of CSF abnormalities or detectable autoantibodies. Early plasma exchange may result in complete neurological recovery. Therefore, clinicians should maintain a high clinical suspicion for immune-mediated neuropathies in patients presenting with rapidly progressive stroke mimics accompanied by autonomic dysfunction.
2026-07-30 | Robot-assisted gait training using a robotic exoskeleton during inpatient rehabilitation in acute Guillain-Barré Syndrome.
A woman in her early 60s with acute Guillain-Barré syndrome (GBS) developed rapidly progressive tetraparesis and respiratory failure requiring non-invasive ventilation. Following intravenous immunoglobulin and medical stabilisation, she entered inpatient rehabilitation with severe weakness, poor truncal control and inability to ambulate. Despite intensive conventional therapy, early gait training was limited. Exoskeleton-based robot-assisted gait training (RAGT) using the Hybrid Assistive Limb (HAL; Cyberdyne Inc, Tsukuba, Japan) was introduced during inpatient rehabilitation as an adjunct to standard therapy. The patient completed 10 HAL sessions over a 15-day period without adverse events. During this time, progressive improvements in ambulatory distance and functional independence were observed. By completion of HAL training, she was able to ambulate 50 m with a walking stick and minimal assistance. She subsequently continued conventional rehabilitation and achieved independent ambulation by discharge. This case suggests that HAL-based RAGT may be a feasible adjunct to inpatient rehabilitation in medically stable patients with acute GBS. The intervention was well tolerated in this patient. Further studies are required to establish patient-selection criteria, optimal timing and the effectiveness of exoskeleton-assisted gait training in GBS.
2026-07-11 | Impact of Gut Microbiota Dysbiosis in Treatment Outcomes of Guillain-Barré Syndrome.
The gut-microbiota plays a significant role in neuro-autoimmune diseases, like Guillain-Barré syndrome (GBS), a post-infectious disorder of the peripheral nervous system (PNS). By altering host immunity, gut dysbiosis may impact the standard therapeutic efficacy of intravenous immunoglobulin (IVIg) and plasma exchange (PE) and thereby, disease progression in GBS. In this study, we investigated the impact of gut-microbiota diversity on therapeutic outcomes of IVIg and PE in patients with GBS. We enrolled 60 patients with GBS categorized into three treatment groups: IVIg-treated, PE, and supportive-care along with 60 age-sex-matched healthy controls from Bangladesh. Fecal microbial DNA was extracted at different timepoints and sequenced. Clinical and sequenced data were analyzed using the Qiime2-Dada2 pipeline. Gut-microbial diversity significantly differed in patients with GBS before and after treatment (Shannon: p = 0.037; Evenness: p = 0.012), particularly in IVIg-treated patients, showing significant changes after 6-month treatment (Shannon: p = 0.034; Evenness: p = 0.011). Beta diversity indicated microbiota restoration in IVIg-treated patients toward a healthy state after treatment (p ≤ 0.001). Phylum Actinobacteriota (p = 0.026), genera Bifidobacterium (p = 0.006), and Enterococcus (p ≤ 0.0001) were relatively abundant in severe patients. Mechanically ventilated patients showed significant gut-microbial diversity (Unweighted-UniFrac; p ≤ 0.001). Biomarker analysis identified a higher abundance of Eubacterium, Bacteroides, Escherichia-Shigella, and Actinomyces in GBS patients. Our exploratory study indicates that gut microbiota dysbiosis is associated with GBS severity and IVIg-treatment outcomes. IVIg-treatment promoted partial restoration of microbial diversity, suggesting a potential immunomodulatory effect mediated through the microbiota. Further studies using meta-transcriptomics are warranted to define functional consequences of microbial shifts in treatment responses of GBS.
antibodies
2026-09-30 | Efgartigimod for Guillain-Barré syndrome: rationale, clinical evidence, and future perspectives.
Guillain-Barré syndrome (GBS) is an acute immune-mediated peripheral neuropathy characterized by rapidly progressive symmetric limb weakness and diminished tendon reflexes, which may be complicated by respiratory muscle paralysis in severe cases. Current first-line treatments primarily consist of intravenous immunoglobulin (IVIg) and plasma exchange (PE), but approximately 20% of patients have an incomplete response to standard therapies. Additionally, issues such as limited supply of blood products, adverse reactions, and contraindications may limit conventional treatments. Efgartigimod alfa is an engineered human IgG1 Fc fragment that targets the neonatal Fc receptor (FcRn) and competitively inhibits FcRn-mediated lgG recycling, thereby promoting the lysosomal degradation of circulating IgG, including pathogenic IgG autoantibodies, and reducing serum IgG levels. Intravenous efgartigimod alfa is approved for AChR antibody-positive generalized myasthenia gravis (gMG), whereas the U.S. approval for chronic inflammatory demyelinating polyneuropathy (CIDP) applies to the subcutaneous efgartigimod alfa/hyaluronidase co-formulation. Neither formulation is currently approved for GBS. Because IgG-mediated autoimmunity contributes to the pathogenesis of a subset of GBS, FcRn blockade provides a biologically plausible therapeutic strategy; however, its relevance may vary according to the underlying immunopathology. This narrative review summarizes the mechanistic rationale, preliminary clinical evidence, and available safety observations regarding efgartigimod in GBS, critically evaluates the limitations of the current evidence, and discusses unresolved questions and priorities for future research.
2026-09-25 | Acute Management of Guillain-Barré Syndrome: A Narrative Review.
Guillain-Barré syndrome (GBS) is a rapidly progressive immune-mediated polyradiculoneuropathy that can cause respiratory failure, autonomic dysfunction, and significant long-term disability. This narrative review examines the acute management of GBS, including supportive care, established immunotherapies, and emerging treatment strategies. Early recognition and close monitoring of respiratory and autonomic function remain essential, particularly during the progressive phase of disease. Intravenous immunoglobulin (IVIg) and plasma exchange remain the primary disease-modifying treatments and have similar overall efficacy, although both primarily accelerate recovery rather than prevent ongoing nerve injury. Their limitations, including treatment-related fluctuations, adverse effects, cost, supply limitations, and the logistical challenges of plasma exchange, highlight the need for more effective therapies. Emerging treatments are increasingly targeting specific mechanisms involved in GBS pathophysiology. Although the C5 inhibitor eculizumab failed to improve outcomes in a phase 3 trial, early results with the upstream C1q inhibitor ANX005 suggest that earlier complement inhibition may reduce nerve injury and improve functional outcomes. Other investigational approaches include IgG-degrading enzymes such as imlifidase, FcRn inhibitors such as efgartigimod, regulatory T-cell therapies, and regenerative strategies. However, most of these treatments lack adequately powered randomized clinical trial data. Important gaps also remain in subtype-specific treatment, nerve regeneration, long-term rehabilitation, treatment-related fluctuations, and access to care. Future research should focus on more targeted and individualized therapies that address both immune-mediated injury and subsequent nerve damage.
2026-09-20 | Pan-Neurofascin Antibody-Associated Nodopathy: A Critical Guillain-Barré Syndrome Mimic in the Differential Diagnosis-Report of Two Cases.
Guillain-Barré syndrome (GBS) is an acute autoimmune polyradiculoneuropathy typically characterized by an ascending sensorimotor deficit with potential involvement of bulbar and respiratory muscles that may necessitate intensive care admission and mechanical ventilation. Standard treatment includes supportive care, management of complications such as weakness, immobility, respiratory failure, autonomic dysfunction and pain, along with early initiation of immunotherapy-either intravenous immunoglobulin (IVIg) or plasma exchange (PE). However, lack of significant clinical improvement following immunotherapy should prompt consideration of alternative diagnoses, including pan-neurofascin antibody-positive autoimmune nodopathy (panNF + AN). In this report, we present two patients presenting with a severe GBS-like neuropathy. Initial treatment with IVIg resulted in either no response or only transient, mild improvement, followed by rapid clinical deterioration to near-complete tetraplegia, respiratory failure, and autonomic and cranial nerve involvement. Both patients were unresponsive to further treatment with a second course of IVIg, PE and corticosteroids. Subsequent diagnostic evaluation revealed the presence of pan-neurofascin antibodies, confirming panNF + AN. This prompted initiation of treatment with rituximab, which resulted in sustained and complete clinical recovery in both cases. A transient or mild clinical response-or an initial lack of response-to standard GBS-treatment followed by rapid and severe deterioration in cases initially presenting as GBS should be considered a red flag warranting evaluation for AN-associated antibodies. Recognition of this important GBS mimic is critical, as it requires an alternative treatment approach with rituximab, which has been associated excellent clinical outcomes.
2026-09-01 | Causal relationship between immune factors and Guillain-Barré syndrome: A Mendelian randomization study.
Guillain-Barré syndrome (GBS) is an immune-mediated polyneurogenic disorder that is strongly correlated with immune factors. However, causal relationships between these factors remain unclear. We used 2-sample Mendelian randomization (MR) and inverse MR analysis. Immune factors were used as the outcome for GBS exposure. Cochrane Q test was used to detect heterogeneity. Simultaneously, the MR-Egger intercept test and MR-Pleiotropy Residual Sum and Outlier tests were used to check for horizontal pleiotropy. MR Steiger was used to estimate the direction of causal inference when the instrumental variables were insufficient in inverse MR. Eighteen immune traits and 1 inflammatory protein were identified as causally involved in the risk of GBS. Reverse MR revealed that GBS was correlated with the levels of eleven immune traits. The sensitivity analyses did not identify any potential heterogeneity or horizontal pleiotropy. Steiger did not find any evidence of reverse causation. We used 2-sample MR to investigate the causal relationship between immune factors and GBS, and our results provide clues for further research.
2026-08-26 | Arboviral infections of the central nervous system: Mechanisms of invasion and long-term consequences.
Arboviruses are a diverse group of vector-borne viruses that cause significant global morbidity and mortality. Beyond classical systemic and febrile symptoms, many arboviruses can induce a spectrum of neurological complications, ranging from mild encephalopathy to severe neuroinvasive disease. This review summarizes current knowledge on major arboviruses from the Flaviviridae, Togaviridae, Peribunyaviridae, and Reoviridae families, emphasizing mechanisms of CNS invasion, neurological manifestations, and relevant case studies or outbreaks. Mechanisms of central nervous system (CNS) invasion are highlighted, including direct viral neurotropism, blood-brain barrier crossing such as Trojan horse-mediated leukocyte trafficking and immune-mediated neuropathology. Clinical syndromes, including encephalitis, myelitis, Guillain-Barré syndrome, and movement disorders, are discussed alongside relevant case studies and outbreak reports. This review provides an integrated perspective on arbovirus-induced neurological disease for clinicians, researchers, and public health professionals.
proteins
2026-06-12 | A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy.
Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are immune-mediated inflammatory neuropathies characterized by T cell- and/or autoantibody-driven injury to peripheral nerves. Although intravenous immunoglobulin (IVIg) is effective in both conditions, its use is limited by high dosing requirements, supply constraints, and manufacturing complexity. NVG-2089 is a recombinant IgG1 Fc-domain protein engineered to selectively agonize type II Fc receptors, promoting anti-inflammatory signaling through expansion of regulatory T cells (Tregs) and upregulation of the inhibitory Fcγ receptor FcγRIIB. Its efficacy in immune complex-mediated disease and T cell-driven neuroinflammation prompted evaluation of its therapeutic potential in an animal model of inflammatory demyelinating neuropathy. We conducted a randomized, blinded preclinical study in the spontaneous autoimmune peripheral polyneuropathy model, a well-established murine model of inflammatory demyelinating neuropathy. Animals were treated with NVG-2089, high-dose IVIg, or vehicle. Outcomes included behavioral performance, nerve electrophysiology, peripheral nerve morphometrics, immunohistochemistry, and flow cytometric immunophenotyping. Both NVG-2089 and IVIg stabilized motor and sensory performance, preserved compound muscle action potential (CMAP) amplitudes, and attenuated demyelination-associated prolongation of distal latency and CMAP duration. Morphometric analyses demonstrated preservation of myelinated fiber density and normalization of g-ratio distributions in both treatment groups. Immunophenotyping indicated an expansion of functionally activated CD25+CD39+ Tregs in the spleen, along with increased FcγRIIB expression on B cells, monocytes, and dendritic cells across systemic and nerve-associated compartments, consistent with engagement of shared anti-inflammatory pathways. NVG-2089 demonstrated robust neuroprotective efficacy comparable to IVIg while requiring a substantially lower protein dose. These findings support NVG-2089 as a promising, dose-efficient alternative to IVIg for the treatment of inflammatory demyelinating neuropathies, including GBS and CIDP.
2026-05-08 | Varicella-zoster virus infection triggering GD3 antibody-positive variant Guillain-Barré syndrome: a case report and literature review.
Bilateral facial palsy variant Guillain-Barré syndrome (GBS) is a distinct clinical subtype. As an acute immune-mediated polyradiculoneuropathy often triggered by infections, varicella-zoster virus (VZV) is a rare yet significant precipitating factor for this variant. Anti-ganglioside antibodies, particularly anti-GD3, are involved in the pathogenesis of GBS, but their significance in VZV-associated bilateral facial palsy subtype remains incompletely elucidated. We report a 46-year-old female who developed acute bilateral facial palsy and limb sensory deficits following VZV infection. Serum anti-ganglioside testing confirmed GD3 IgG positivity, and cerebrospinal fluid analysis revealed albuminocytological dissociation. Nerve conduction studies supported a demyelinating polyneuropathy, and the patient showed significant improvement after intravenous immunoglobulin therapy. This case suggests that VZV may act as a potential trigger for GD3 antibody-positive variant GBS. Early immunotherapy may improve outcomes, emphasizing the need for systematic antibody testing in atypical presentations of this variant GBS. Further studies are required to clarify the pathophysiological role of GD3 antibodies in VZV-associated variant GBS.
2025-11-05 | Diagnostic and therapeutic potential of resolvin D1 in Guillain-Barré syndrome.
Most neuroimmune diseases are incurable and require lifelong immunotherapy, whereas Guillain-Barré syndrome (GBS), a peripheral nervous system autoimmune disorder, has a relatively favorable prognosis. Investigating the molecular disparities underlying recovery between GBS and other neuroimmune diseases may facilitate the development of innovative therapeutic strategies. This study explored the diagnostic and therapeutic potential of resolvin D1 (RvD1), a specialized pro-resolving mediator that promotes inflammation resolution and tissue regeneration, in GBS and its animal model experimental autoimmune neuritis (EAN). Serum RvD1 levels were measured in 218 participants from two cohorts, including healthy controls (HCs), GBS patients, and those with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), or stroke. The diagnostic accuracy was evaluated via the area under the receiver operating characteristic (ROC) curve (AUC). RvD1 was administered to EAN and experimental autoimmune encephalomyelitis (EAE, an MS animal model) to assess its therapeutic efficacy. Serum RvD1 was elevated in GBS patients, demonstrating high diagnostic accuracy in differentiating GBS patients from HCs (cohort 1: AUC 0.72; cohort 2: AUC 0.93), MS/NMOSD patients (cohort 1: AUC 0.83), and stroke patients (cohort 1: AUC 0.68). The RvD1 level continued to increase as GBS progressed and was positively correlated with disease severity, ventilator dependence, and axonal neuropathy. In EAN, RvD1 and its synthetase/receptor were upregulated in serum, spleen, and sciatic nerve, exhibiting tissue-specific inflammation resolution patterns across disease phases. RvD1 treatment promoted inflammation resolution in EAN, as evidenced by attenuated disease severity and autoimmune responses, with its therapeutic effect was translatable to EAE. RvD1 may serve as a biomarker for both diagnosing GBS and monitoring disease severity. It represents a potential immunotherapeutic agent for GBS and other neuroimmune disorders. Elucidating the molecules associated with recovery in patients with GBS may facilitate the discovery of novel therapeutic strategies for neuroimmune disorders.
2025-10-14 | Exacerbation of demyelinating polyneuropathy after adoptive cell therapy with tumour-infiltrating lymphocytes by metastatic melanoma.
Adoptive cell therapy (ACT) with tumour-infiltrating lymphocytes (TIL) is an effective personalised immunotherapy for patients with advanced pretreated melanoma. For TIL-ACT, tumour-specific T cells are expanded from excised tumour samples and stimulated in cell culture with interleukin-2 (IL-2). The resulting autologous tumour-infiltrating lymphocytes are reinfused to the patient after a non-myeloablative lymphodepleting chemotherapy with cyclophosphamide and fludarabine. Thereafter, activation of tumour-infiltrating lymphocytes in the patient is supported by the administration of high-dose IL-2. Although effective, there is a need for enhancement of TIL-ACT in terms of effectiveness and toxicity. Most of the toxicity in this multistep, complex treatment regimen is due to the preparative chemotherapy and high-dose IL-2 treatment. At University Hospital Basel, we are currently evaluating an experimental approach of TIL-ACT in which we replace high-dose IL-2 by in vivo tumour-infiltrating lymphocyte activation with ANV419, a novel antibody-cytokine fusion protein consisting of IL-2 fused to an anti-IL-2 monoclonal antibody, in an ongoing phase I trial (BaseTIL-03M). The primary endpoint of the study is safety. We herein describe the case of a patient included in the BaseTIL-03M trial with chronic inflammatory demyelinating polyneuropathy who received TIL-ACT with ANV419 and developed an acute polyneuropathy of Guillain-Barré syndrome.
2025-08-24 | Design of Hyperglycosylated Zika Virus E Proteins that Focus Antibody Recognition on the Complex E Dimer Epitope.
Zika virus (ZIKV) and dengue virus serotypes 1-4 (DENV1-4) are flaviviruses spread by Aedes mosquitoes. ZIKV infection can cause Guillain-Barré syndrome and microcephaly, while severe dengue can lead to hemorrhagic fever and death. DENV infection of ZIKV-immune individuals is linked to severe clinical outcomes due to antibody-dependent enhancement (ADE) of infection. Thus, the development of broadly protective vaccines is an important objective. We focus on the E dimer epitope (EDE) of ZIKV, which is targeted by broadly neutralizing antibodies that protect against ZIKV and DENV1-4. We engineered ZIKV E dimer variants containing non-native asparagine-linked glycosylation sites to block antibody responses to regions outside the EDE using a structure-based iterative design approach. One candidate, SC30m53, bound EDE mAbs but not other mAbs and induced a potently neutralizing response against ZIKV and moderately cross-neutralizing responses against DENV1-3 in mice. These findings suggest that hyperglycosylation provides a promising approach to focusing the immune response on key epitopes.
other
2026-07-17 | COVID-19 mRNA Vaccination Reduces Guillain-Barré Syndrome Risk: Evidence from a Large Longitudinal Cohort Study.
The association between COVID-19 vaccination and Guillain-Barré syndrome (GBS) has been previously investigated with inconsistent results, largely due to limited data and lack of concurrent controls. To address this problem, a large longitudinal cohort study was conducted using National COVID Cohort Collaborative (N3C) data. While COVID-19 infection was associated with increased GBS occurrence, COVID-19 vaccination was associated with significantly reduced GBS risk relative to unexposed (unvaccinated and uninfected) control, corresponding to a 61% lower 30-day risk (incidence risk ratio: IRR = 0.39, P < 0.01), consistent with multivariable Cox regression showing a similar reduction (adjusted hazard ratio: aHR = 0.41, P < 0.01). This protective association was observed only among recipients of mRNA vaccines (BNT162b2: IRR = 0.38, P < 0.01; mRNA-1273: IRR = 0.24, P < 0.01), but not among recipients of adenoviral-vector vaccines (IRR = 1.38, P > 0.05). Prior COVID-19 vaccination also reduced infection-associated GBS risk. Additional factors associated with GBS risk included sex, vaccine dose, and pre-existing comorbidities such as stroke, neurological disorders, and autoimmune diseases. Overall, our N3C large-scale study provides evidence that COVID-19 mRNA vaccination reduces GBS risk, supporting the safety profile of mRNA vaccines and warranting further mechanistic investigation.
2026-04-01 | The EGR1/ZFP36 axis governs glycosphingolipid metabolic reprogramming in monocyte-derived macrophages in guillain-barré syndrome.
Guillain-Barré syndrome (GBS) is an immune-mediated demyelinating disorder of peripheral nerves with an unclear pathogenesis. This study integrated GBS clinical single-cell data with EAN model transcriptome data, establishing in vivo and in vitro experimental systems to reveal, for the first time, a novel mechanism involving EGR1-ZFP36 and its mediated metabolic reprogramming in GBS pathogenesis. Findings indicated that the transcription factor EGR1 and its predicted target gene ZFP36 were downregulated in both GBS patients and EAN rats. Molecular interaction validation confirmed that EGR1 directly bound to and activated the transcription of ZFP36. Transcriptomic and metabolomic analyses revealed that the EGR1/ZFP36 axis specifically drove macrophage reprogramming toward a glycosphingolipid metabolism-active state. Functionally, EGR1 overexpression promoted the expression of key glycosphingolipid metabolism genes (HEXA, HEXB) by upregulating ZFP36, thereby facilitating polarization toward the anti-inflammatory M2 phenotype. Animal experiments further demonstrated that EGR1 overexpression improved motor function and ameliorated myelin damage in the EAN model, with this protective effect being mediated by ZFP36. Collectively, this study reveals that EGR1 drives glycosphingolipid metabolic reprogramming in monocyte-derived macrophages by transcriptionally activating ZFP36, thereby regulating cellular polarization and participating in the demyelination process of GBS. This discovery not only provides a novel perspective on understanding the immunometabolic mechanisms of GBS but also lays a theoretical foundation for potential therapeutic strategies targeting the EGR1-ZFP36-glycosphingolipid metabolism axis.
2025-12-30 | A Review of Cutaneous Viral Infections and Their Potential Role in Neurologic Diseases.
Background: Cutaneous viral infections, defined as viral pathogens that either primarily affect the skin (e.g., herpesviruses, enteroviruses) or frequently produce dermatologic manifestations despite systemic tropism (e.g., HIV, SARS-CoV-2), can trigger systemic inflammatory and neurotropic responses that extend their impact to the nervous system. A growing body of evidence suggests that viruses with dermatologic manifestations may play a significant role in the pathogenesis of neurologic disorders. Summary: Although individual viruses have been studied in isolation, the skin-brain axis in viral infections remains incompletely characterized. This review synthesizes existing knowledge and highlights gaps in understanding the mechanisms linking cutaneous viral infections to neurologic disease. We explore the principal mechanisms linking viral skin infections to central and peripheral nervous system damage, including direct neuroinvasion, immune-mediated injury, and vascular or endothelial dysfunction. Particular attention is given to herpesviruses, retroviruses, enteroviruses, and respiratory viruses, which have been associated with conditions such as dementia, multiple sclerosis, myelopathies, Guillain-Barré syndrome, and the post-acute neurologic sequelae of COVID-19. Furthermore, we discuss the role of neuroinflammation in viral-associated neurodegeneration and highlight emerging evidence supporting the recombinant zoster vaccine (Shingrix) as a potential modulator of neuroinflammatory processes and a protective factor against dementia. Conclusions: Cutaneous viral infections extend beyond local skin pathology, contributing to a broad spectrum of neurologic complications through intertwined infectious and inflammatory mechanisms. A clearer understanding of how peripheral viral activity shapes central nervous system vulnerability remains a major unmet need. A multidisciplinary approach integrating dermatologic and neurologic perspectives is essential for early recognition and prevention. While observational studies suggest that zoster vaccination may reduce viral reactivation and modulate neuroinflammatory pathways, definitive evidence of neuroprotection is still lacking. Future studies should clarify causal relationships, test mechanistic hypotheses regarding skin-brain immune crosstalk, and explore vaccine-mediated neuroprotection as a novel therapeutic strategy.
2025-10-28 | The Yin and Yang of Antibodies in Viral Infectious Diseases.
Antibodies are a cornerstone of the adaptive immune response, serving as key defenders against viral infections; however, they can also act as a double-edged sword, contributing to immune-mediated pathologies. This review advances a "Yin-Yang" framework to integrate the dual activities of antibodies. The protective 'Yin' functions are driven by high-affinity antibodies generated through processes like somatic hypermutation and class-switch recombination. These antibodies execute viral neutralization, activate the complement system, and engage Fc receptors (FcRs) to drive antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis. These mechanisms form the immunological basis of effective vaccines, which aim to elicit durable and functionally specialized antibody isotypes like IgG and mucosal IgA. Conversely, the pathogenic 'Yang' of the response can be detrimental. This includes antibody-dependent enhancement (ADE) of infection, notably observed with flaviviruses, and the development of autoimmunity through mechanisms like molecular mimicry and bystander activation, which can lead to conditions such as multiple sclerosis and Guillain-Barré Syndrome. The balance between protection and pathology is tipped by a confluence of factors. These include viral evasion strategies like antigenic mutation and glycan shielding, as well as host-based determinants such as genetic polymorphisms in FcRs, immune history, and the gut microbiome. Understanding these molecular determinants informs the rational design of next-generation interventions. Promising strategies, such as Fc-region glyco-engineering and the design of tolerogenic vaccines, aim to selectively promote protective functions while minimizing pathological risks, offering a clear path forward in combating viral threats.
2025-10-18 | A systematic review of CRISPR applications in demyelinating peripheral nervous system disorders.
This review evaluates CRISPR-based strategies for myelin regeneration in peripheral demyelinating disorders, with a focus on Guillain - Barré syndrome (GBS) and Charcot - Marie - Tooth disease type 1A (CMT1A). It aims to identify current therapeutic approaches, delivery systems, and gaps in the literature. A systematic literature search was conducted across PubMed, Scopus, Web of Science, and Google Scholar for studies published from 2010 onward, following PRISMA guidelines. Study quality was assessed using OHAT and SYRCLE tools, and 14 articles met the inclusion criteria. In GBS, CRISPR interventions primarily targeted antiviral immune regulation (AXL, IFI6, IFNL2), inhibition of viral entry mechanisms (Integrin αvβ5, SPCS1), and Schwann cell repair. In CMT1A, therapeutic approaches focused on correcting PMP22 overexpression. Lentiviral transduction was the most frequently used delivery method, with no major adverse effects reported. However, most studies were in vitro, and only two were in vivo, highlighting the need for further validation in animal models. CRISPR technology shows considerable potential for addressing peripheral nerve demyelination through precise genetic modifications that may enhance Schwann cell function and support myelin repair. Nevertheless, the field remains at an early discovery stage, with no near-term clinical applicability demonstrated.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
11 orphan drug designations for Guillain-Barré syndrome.
11 orphan drug designations for Guillain-Barré syndrome.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
Humanised IgG4 monoclonal antibody against C1q | antibodies | EMA | Sinclair Regulatory Consulting Europe Limited | |
Eculizumab [Soliris] | antibodies | EMA | Alexion Europe | |
eculizumab | antibodies | FDA | Alexion Pharmaceuticals, Inc. | |
imlifidase | proteins | FDA | Hansa Medical AB | |
humanized IgG4 monoclonal antibody binding to human C1q | antibodies | FDA | Annexon, Inc. | |
Recombinant protein derived from the saliva of the Ornithodoros moubata tick | proteins | EMA | — | Akari Malta Limited |
nomacopan | proteins | FDA | — | Akari Therapeutics Plc |
immune globulin (human) | antibodies | FDA | — | Octapharma USA, Inc. |
Fampridine | small molecules | EMA | — | Ulrich Granzer |
4-Aminopyridine | small molecules | FDA | Merz Pharmaceuticals LLC | |
Immune Globulin Intravenous (human) | antibodies | FDA | — | ZLB Bioplasma AG |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.